ZBIO — Zenas BioPharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1953926 ·
Last close
$31.09
Market Cap
$1.96B
52W High
$34.05
52W Low
$16.41
ADV30
1,048,785
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -77,350,000 | -80,987,000 | 747,682,000 | 500,224,000 | 411,853,000 |
| Dec 2025 | 0 | — | -71,312,000 | -240,442,000 | 383,640,000 | 110,641,000 | 141,496,000 |
| Sep 2025 | 0 | — | -47,580,000 | -51,499,000 | 322,018,000 | 115,565,000 | 125,590,000 |
| Jun 2025 | 0 | — | -55,163,000 | -52,223,000 | 293,085,000 | 44,006,000 | 53,459,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-210,478,000
Investing CF
$-134,001,000
Financing CF
$648,660,000
CapEx
$-35,020,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.47
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-846,115,000
Inventory
—
Receivables
—
ST Investments
$216,981,000
EBIT TTM
$-407,515,000
Pretax Income TTM
$-425,025,000
Interest Exp TTM
$6,631,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-251,366,000
Free Cash Flow
$-166,289,872
Enterprise Value
$1,586,938,112
Total Cash
$717,204,992
Total Debt
$266,828,992
Shares Out
63,133,377
Trailing EPS
$-9.10
Book Value
$4.44
ROE
-137.1%
ROA
-29.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,000,000 | -211,385,000 | -377,737,000 | 383,640,000 | 141,496,000 | — | -172,333,000 |
| Dec 2024 | 5,000,000 | -163,888,000 | -156,988,000 | 369,968,000 | 57,510,000 | — | -119,674,000 |
| Dec 2023 | 50,000,000 | -27,147,000 | -37,124,000 | 68,180,000 | 293,901,000 | — | -30,529,000 |
| Dec 2022 | 0 | -75,199,000 | -119,282,000 | 74,579,000 | 266,865,000 | — | -65,652,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.27
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | $1.96B | $40.94 | — |
| URGN | UroGen Pharma Ltd. | $1.97B | $40.45 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.95B | $15.18 | — |
| HCM | HUTCHMED (China) Ltd | $1.98B | $11.39 | — |
| PGEN | PRECIGEN, INC. | $1.94B | $5.45 | — |
News headlines (Yahoo Finance, 1h cache)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-17 20:15 · Yahoo
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
2026-07-17 12:13 · Yahoo
Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
2026-07-10 13:58 · Yahoo
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
2026-06-21 11:31 · Yahoo
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
2026-06-11 20:15 · Yahoo
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Fresh Economic Signals
2026-06-03 13:10 · Yahoo
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Publis
2026-06-02 23:05 · Yahoo
A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness
2026-06-01 12:06 · Yahoo
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
2026-05-28 11:05 · Yahoo
Insiders Buy the Dip in These 2 Crushed Stocks With Strong Buy Ratings
2026-05-21 17:58 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.